ArticleAnnals of gastroenterological surgery2026
Mac-2 Binding Protein Glycosylation Isomer (M2BPGi)-Based Risk Stratification Refined by Tumor Metabolic Activity in Hepatocellular Carcinoma.
Article in Annals of gastroenterological surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To evaluate the prognostic significance of preoperative Mac-2 binding protein glycosylation isomer (M2BPGi) and determine whether tumor metabolic activity provides additional risk stratification after hepatic resection for hepatocellular carcinoma (HCC). Methods: We retrospectively analyzed 291 patients with HCC who underwent hepatic resection at a single Japanese institution between 2015 and 2023 and had available preoperative M2BPGi and 18F-fluorodeoxyglucose positron emission tomography/computed tomography data. Associations with clinicopathological features, recurrence-free survival (RFS), and overall survival (OS) were evaluated. Results: High M2BPGi was associated with impaired liver function and F3-F4 fibrosis but not with tumor-related features or tumor metabolic activity. In contrast, high tumor metabolic activity was associated with higher des- Conclusions: Preoperative M2BPGi identifies fibrosis-related risk after HCC resection, whereas tumor metabolic activity further distinguishes patients with particularly poor outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.